Honduras Pharmaceuticals and Healthcare Report Q2 2016
BMI View: Over the next ten years, there will be limited demand for advanced medicines within Honduras'public healthcare system. Low-cost generic drugs will continue to dominate the local market. Thepharmaceutical market in Honduras will continue to be extremely unattractive to multinational drugmakersdue to the small market size, low growth rate and the fragmented, opaque and often-questionable publicprocurement process.
Headline Expenditure Projections
Pharmaceuticals: HNL10.33bn (USDb473mn) in 2015 to HNL10.70bn (USD480mn) in 2016; +3.5% inlocal currency terms, and +1.0% in US dollar terms. Our forecast has not changed since Q215.
Healthcare: HNL37.83bn (USDb1.73bn) in 2015 to HNL40.95bn (USD1.83n) in 2016; +8.3% in localcurrency terms, and +5.6% in US dollar terms. Our forecast has been revised downwards since Q415 due torevised macroeconomic data.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook